Übersicht			Auf mobile öffnen

Lieferstatus:	Auf Bestellung (Lieferzeit unbekannt)
Veröffentlichung:	Dezember 2010
Genre:	Naturwissensch., Medizin, Technik
ISBN:	9780195393927
EAN-Code:	9780195393927
Verlag:	Oxford University Press, USA
Einband:	Gebunden
Sprache:	English
Dimensionen:	H 241 mm / B 163 mm / D 21 mm
Gewicht:	476 gr
Seiten:	208
Bewertung:	Titel bewerten / Meinung schreiben

Inhalt:

Each year, nearly 700,000 people in the United States will have a stroke. A drug known as tPA can drastically reduce the long-term disability associated with stroke if it is administered within the first three hours after the event occurs. Many of those who are lucky enough to be treated with tPA have made full recoveries--to the extent that one can hardly believe they suffered a "real" stroke. Others still do not receive the drug; many suffer permanent disabilities, and many die. Authors Zivin and Simmons argue that most Americans have never heard of tPA. Why would such an effective pharmaceutical, one that has a remarkable rate of success with the third leading killer of Americans, be so disregarded? tPA for Stroke: The Story of a Controversial Drug explains the drug's beginnings within pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfortunate political, fiscal, and medical circumstances. Readers will learn about an extraordinary treatment for acute stroke that they may then seek if a stroke occurs and anyone interested in the unique process of drug development, marketing, and promotion, told from an insider's perspective, will have an interest intPA for Stroke.